Global Methenamine Hippurate Tablets Market Segments 2024, Forecast To 2033
5 Mar, 2024
The methenamine hippurate tablets market has shown robust growth, increasing from $8.97 billion in 2023 to $9.63 billion in 2024, with a 7.4% CAGR. Traditional UTI treatment and antibiotic resistance concerns contributed to historic growth. The market is expected to reach $12.83 billion in 2028, reflecting a 7.4% CAGR. Anticipated trends involve growing UTI prevalence, research advancements, and preference for non-antibiotic solutions, aligning with the healthcare industry's focus on preventive therapies and patient-centric care.
Global Methenamine Hippurate Tablets Market Key Driver
The methenamine hippurate tablets market is poised for growth driven by an increasing geriatric population. With individuals aged 60 and above vulnerable to urinary tract infections, the demand for methenamine hippurate tablets rises. The World Health Organization projects that by 2030, one in six people globally will be aged 60 or older. In 2021, the global population of those over 60 was 1.4 billion, expected to double by 2050. This demographic shift propels the demand for effective treatments, positioning the methenamine hippurate tablets market for sustained growth.
Get A Free Sample Of The Global Methenamine Hippurate Tablets Market ReportGlobal Methenamine Hippurate Tablets Market Segments
The methenamine hippurate tablets market covered in this report is segmented –
1) By Type: 20 Tablets Or Bottle, 6 Tablets Or Bottle
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By Application: Uncomplicated UTIs, Healthcare-associated UTIs
4) By End User: Hospitals, Homecare, Specialty Clinics, Others End Users
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the methenamine hippurate tablets market in 2023. The regions covered in the methenamine hippurate tablets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Methenamine Hippurate Tablets Industry Players
Validus Pharmaceuticals LLC; Alvogen Lux Holdings S.ÀR.L.; Micro Labs Inc.; Aurobindo Pharma; Edenbridge Pharmaceuticals LLC; Kreative Organics; CorePharma LLC; Amneal Pharmaceuticals Inc.; Viatris Inc.; County Line Pharmaceuticals; Mylan N.V.; McKesson Corporation; Nuray Chemicals Private Limited; Chemische Fabrik Berg GmbH; Siegfried AG; Sun Pharmaceutical Industries Ltd.; Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; Cadila Healthcare Ltd.; Torrent Pharmaceuticals Ltd.; Glenmark Pharmaceuticals Ltd.; Zydus Pharmaceuticals Ltd.; Lupin Ltd.; Alkem Laboratories Ltd.; Ipca Laboratories Ltd.; Granules India Ltd.; Ajanta Pharma Ltd.; Teva Pharmaceutical Industries Ltd.; Apotex Pharmachem Inc.; Taro Pharmaceutical Industries Ltd.; Sandoz International GmbH
Get The Full Global Methenamine Hippurate Tablets Market Report
AIOps Methenamine Hippurate Tablets Market Overview
Methenamine hippurate tablets are used as a medicine to prevent or control recurring urinary tract infections caused by specific bacteria. It is not used for any other active infections.
Methenamine Hippurate Tablets Global Market Report 2023 provides data on the global methenamine hippurate tablets market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The methenamine hippurate tablets market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.